Skip to main content
. 2017 May 24;8(31):51608–51620. doi: 10.18632/oncotarget.18209

Figure 4. PFS and OS in newly diagnosed MM patients with t(4;14) after receiving bortezomib-based or other chemotherapies.

Figure 4

(A)-(B): The MB4-1 patients had longer PFS (P=0.004) and OS (P< 0.001) than that of MB4-2/MB4-3 subgroup. (C)-(D): The MB4-1 patients treated with bortezomib-based chemotherapy had longer PFS (P=0.03) and OS (P=0.048) than those treated with other chemotherapies. (E)-(F): The MB4-2/MB4-3 patients had similar PFS and OS between bortezomib-based and other chemotherapies groups (PFS: P=0.074; OS: P=0.266).